Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Medtronic completes enrollment in first of two CURE-AF clinical trials

Medtronic, Inc., today announced completion of patient enrollment in the first of two studies in the company's CURE-AF (Concomitant Utilization of Radiofrequency Energy for Atrial Fibrillation) clinical trial.

4 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

Intouch Health completes $10M private placement through Beringea-led financing round

InTouch Technologies®, Inc. (d.b.a. InTouch Health®), the world leader in Remote Presence Total Telemedicine solutions, announced today the completion of a private placement of $10 million. The financing round was led by Michigan-based Beringea through its InvestMichigan! Growth Capital Fund, which provides venture and expansion-stage capital to businesses with operations in Michigan.

3 May 2010

Investigators examine effects of family-oriented interventions on adults with chronic physical diseases

In the current issue of Psychotherapy and Psychosomatics a group of German investigators examines the literature concerned with the effects of interventions involving the family in the treatment of patients with chronic disease.

3 May 2010

Study shows link between short cycles of sleep, stroke and SCI in elderly hypertensive patients

Data presented today at the American Society of Hypertension, Inc.'s 25th Annual Scientific Meeting and Exposition demonstrate a link between short cycles of sleep, stroke and silent cerebral infarct, or "silent strokes," in elderly hypertensive patients.

3 May 2010

Leptin hormone controls immune’s response to sepsis: Study

The hormone leptin, typically associated with body weight regulation, works within the central nervous system (CNS) to aid the immune system's defense against sepsis, researchers say.

3 May 2010

AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia

AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the submission of its Complete Response to the October 2006 Approvable Letter issued by the U.S. Food and Drug Administration (FDA) for Zenvia™ (dextromethorphan/quinidine) for the treatment of pseudobulbar affect (PBA). AVANIR expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval of Zenvia in the fourth calendar quarter of 2010.

3 May 2010

New 3-D mapping and labeling system reduces scan time and improves work flow

Researchers have developed an automated 3-D mapping and labeling system that reduces scan time and improves the work flow, efficiency, and accuracy of routine freehand ultrasound exams, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

3 May 2010

Left ventricular mass may help predict future cardiovascular and renal outcomes: Study

Data presented today at the American Society of Hypertension, Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) indicate that in men with high cardiovascular risk, left ventricular mass may help better predict future cardiovascular and renal outcomes, including hemodialysis.

3 May 2010

Majority of patients who appear healthy may be at risk for cardiovascular disease

Three separate studies announced today at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010) examined the cardiovascular consequences of relatively healthy patients - those who were asymptomatic and not classified as hypertensive or diabetic - and found that many patients who appear healthy may still be at risk for cardiovascular disease.

3 May 2010

VIMOVO delayed-release tablets receive FDA approval

AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration has approved VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

3 May 2010

New tool may help neurologists predict candidates for organ donation

A new tool may help neurologists predict which coma patients may be candidates for organ donation, according to a study published in the April 27, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

3 May 2010

Study finds multiple brain regions used to decipher sentences

A new study from the University of Rochester finds that there is no single advanced area of the human brain that gives it language capabilities above and beyond those of any other animal species.

30 Apr 2010

Excess urinary protein excretion increases risk of kidney, heart complications in people with hypertension

Healthy people with high blood pressure who excrete a slight excess of protein in the urine raise their risk of developing kidney and heart complications. According to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN), more attention should focus on the potential health effects of urinary protein excretion in individuals with high blood pressure (hypertension).

30 Apr 2010

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

30 Apr 2010

Jiangsu Yanshen receives SFDA disciplinary notice for substandard quality human use rabies vaccine

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd. has received disciplinary notice from China's State Food and Drug Administration regarding its production of substandard quality human use rabies vaccine.

29 Apr 2010

ev3's first-quarter 2010 net sales up 21%

ev3 Inc., a global endovascular device company, today reported financial results for its fiscal first quarter and updated financial guidance for 2010. ev3's net sales totaled $123.9 million in the first quarter of 2010 compared to $100.4 million in the same quarter of the prior year. Excluding $2.9 million of positive impact due to foreign currency exchange rates, net sales increased 21% versus the prior year quarter.

29 Apr 2010

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Individuals diagnosed with a brain arteriovenous malformation, an abnormal tangle of arteries and veins, are at an increased risk of vessel rupture and bleeding that can cause stroke and permanent brain damage.

29 Apr 2010

Researchers develop lottery game to assess extent of spatial neglect

Patients recovering from stroke sometimes behave as if completely unaware of one half of the world: colliding with obstacles on their left, eating food only from the right side of their plate, or failing to dress their left side. This puzzling phenomenon is termed "spatial neglect" and it affects roughly 45% of patients suffering from a stroke in the right side of the brain.

29 Apr 2010

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.

29 Apr 2010

Stroke News and Research

Further Reading

Medtronic completes enrollment in first of two CURE-AF clinical trials

FDA issues advisory on prostate cancer drugs

Intouch Health completes $10M private placement through Beringea-led financing round

Investigators examine effects of family-oriented interventions on adults with chronic physical diseases

Study shows link between short cycles of sleep, stroke and SCI in elderly hypertensive patients

Leptin hormone controls immune’s response to sepsis: Study

AVANIR Pharmaceuticals announces filing of Complete Response to FDA Approvable Letter for Zenvia

New 3-D mapping and labeling system reduces scan time and improves work flow

Left ventricular mass may help predict future cardiovascular and renal outcomes: Study

Majority of patients who appear healthy may be at risk for cardiovascular disease

VIMOVO delayed-release tablets receive FDA approval

New tool may help neurologists predict candidates for organ donation

Study finds multiple brain regions used to decipher sentences

Excess urinary protein excretion increases risk of kidney, heart complications in people with hypertension

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

Jiangsu Yanshen receives SFDA disciplinary notice for substandard quality human use rabies vaccine

ev3's first-quarter 2010 net sales up 21%

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Researchers develop lottery game to assess extent of spatial neglect

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News